EyePoint Pharmaceuticals (EYPT) News Today $7.48 +0.21 (+2.89%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 3.4% - Should You Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 3.4% Higher - What's Next?January 16 at 1:25 PM | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)January 16 at 7:00 AM | globenewswire.comBrokerages Set EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Price Target at $26.63January 15 at 1:41 AM | americanbankingnews.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Rating of "Buy" from AnalystsShares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) have earned an average rating of "Buy" from the ten analysts that are presently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a buy rating. The average 1 year price target among brokJanuary 12, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 9.8% - Here's WhyEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Down 9.8% - Should You Sell?January 10, 2025 | marketbeat.comCitigroup Begins Coverage on EyePoint Pharmaceuticals (NASDAQ:EYPT)January 10, 2025 | americanbankingnews.comEyePoint Pharmaceuticals Strengthens Board with New AppointmentJanuary 9, 2025 | markets.businessinsider.comEyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D., FASRS to Board of DirectorsJanuary 8, 2025 | markets.businessinsider.comOptimistic Buy Rating for EyePoint Pharmaceuticals: Potential of Duravyu in Diabetic Macular EdemaJanuary 8, 2025 | markets.businessinsider.comEyePoint Appoints Renowned Retina Specialist and Industry Pioneer Reginald J. Sanders, M.D.January 8, 2025 | globenewswire.comCitigroup Initiates Coverage of EyePoint Pharmaceuticals (EYPT) with Buy RecommendationJanuary 8, 2025 | msn.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Gap Up - Here's WhyJanuary 7, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Now Covered by Analysts at CitigroupCitigroup initiated coverage on shares of EyePoint Pharmaceuticals in a research note on Tuesday. They set a "buy" rating and a $33.00 target price for the company.January 7, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 9.6% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 9.6% - Here's WhyJanuary 6, 2025 | marketbeat.comPositive Outlook for EyePoint Pharmaceuticals Driven by Promising Prospects in the DME MarketJanuary 2, 2025 | markets.businessinsider.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Purchased by Geode Capital Management LLCGeode Capital Management LLC boosted its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 16.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,199,056 sharJanuary 2, 2025 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 5.8% - What's Next?EyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 5.8% - Here's WhyDecember 31, 2024 | marketbeat.comBarclays PLC Grows Holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Barclays PLC increased its holdings in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 410.4% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 245,045 shares of the company's stoDecember 27, 2024 | marketbeat.comFranklin Resources Inc. Buys 362,399 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Franklin Resources Inc. increased its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 9.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 4,012,048 shareDecember 19, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Up 6.4% - Here's WhyEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Up 6.4% - Here's What HappenedDecember 17, 2024 | marketbeat.comEyePoint to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 17, 2024 | markets.businessinsider.comShort Interest in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Decreases By 6.4%EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) was the target of a significant drop in short interest in November. As of November 30th, there was short interest totalling 9,250,000 shares, a drop of 6.4% from the November 15th total of 9,880,000 shares. Based on an average daily volume of 855,700 shares, the days-to-cover ratio is currently 10.8 days.December 16, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week Low - Should You Sell?EyePoint Pharmaceuticals (NASDAQ:EYPT) Reaches New 52-Week Low - Should You Sell?December 16, 2024 | marketbeat.comEyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)December 16, 2024 | globenewswire.comPoint72 Asset Management L.P. Cuts Stake in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Point72 Asset Management L.P. lessened its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 28.4% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 451,318 shares of the company's stock after selling 179,451 shares duringDecember 9, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading 7% Higher - Time to Buy?EyePoint Pharmaceuticals (NASDAQ:EYPT) Shares Up 7% - Here's WhyDecember 6, 2024 | marketbeat.comEyePoint Pharmaceuticals Poised for Growth with Promising DME Treatment DuravyuDecember 4, 2024 | markets.businessinsider.comPatient Square Capital LP Makes New $10.88 Million Investment in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Patient Square Capital LP purchased a new position in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 1,361,979 shares of the cDecember 4, 2024 | marketbeat.comEyePoint Announces First Patient Dosed in Second Global Phase 3 LUCIA Clinical Trial of DURAVYU™ for the Treatment of Wet Age-Related Macular DegenerationDecember 4, 2024 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Sells 71,796 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)Connor Clark & Lunn Investment Management Ltd. lessened its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 59.5% in the third quarter, according to its most recent filing with the SEC. The firm owned 48,791 shares of the company's stock after selling 71,796 sharDecember 1, 2024 | marketbeat.comEyePoint reports inducement grants under NASDAQ listing ruleNovember 18, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 8.5% - What's Next?EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 8.5% - What's Next?November 15, 2024 | marketbeat.comResearch Analysts Issue Forecasts for EYPT FY2024 EarningsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) - Investment analysts at HC Wainwright lowered their FY2024 earnings per share (EPS) estimates for EyePoint Pharmaceuticals in a research report issued to clients and investors on Monday, November 11th. HC Wainwright analyst Y. Chen now aNovember 14, 2024 | marketbeat.comEyePoint Pharmaceuticals: Low Price And Good Data Create An OpportunityNovember 14, 2024 | seekingalpha.comEyePoint Pharmaceuticals: Buy Rating Backed by Promising Clinical Developments and Strong Financial PositionNovember 11, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Cut to $22.00 by Analysts at HC WainwrightHC Wainwright dropped their price objective on shares of EyePoint Pharmaceuticals from $30.00 to $22.00 and set a "buy" rating for the company in a research report on Monday.November 11, 2024 | marketbeat.comRobert W. Baird Issues Pessimistic Forecast for EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock PriceRobert W. Baird reduced their target price on shares of EyePoint Pharmaceuticals from $38.00 to $33.00 and set an "outperform" rating on the stock in a research note on Monday.November 11, 2024 | marketbeat.comEyePoint Pharmaceuticals Advances in Retinal TherapeuticsNovember 9, 2024 | markets.businessinsider.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Price Target Raised to $33.00Chardan Capital upped their price objective on shares of EyePoint Pharmaceuticals from $28.00 to $33.00 and gave the stock a "buy" rating in a report on Friday.November 8, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 5.4% - Here's What HappenedEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 5.4% - Time to Sell?November 4, 2024 | marketbeat.comEyePoint Pharmaceuticals Announces Participation at Upcoming Investor ConferencesNovember 4, 2024 | globenewswire.comEyePoint Pharmaceuticals Announces Closing of Upsized Public Offering and Full Exercise of Option to Purchase Additional SharesOctober 31, 2024 | globenewswire.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Strong Trading Volume - What's Next?EyePoint Pharmaceuticals (NASDAQ:EYPT) Sees Large Volume Increase - Here's What HappenedOctober 30, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Quotes, Forecast and News SummaryOctober 30, 2024 | benzinga.comEyePoint Pharmaceuticals Announces Pricing of Upsized Public OfferingOctober 29, 2024 | globenewswire.com‘Really competitive’ tax breaks keep EyePoint manufacturing in Mass.October 29, 2024 | bizjournals.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Trading Down 6.5% - Should You Sell?EyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 6.5% - Time to Sell?October 29, 2024 | marketbeat.comEyePoint Pharmaceuticals (NASDAQ:EYPT) Stock Rating Reaffirmed by Chardan CapitalChardan Capital restated a "buy" rating and set a $28.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Tuesday.October 29, 2024 | marketbeat.comEyePoint Pharmaceuticals Inc.October 29, 2024 | wsj.comEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Recommendation of "Buy" by AnalystsEyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Get Free Report) has earned a consensus rating of "Buy" from the nine analysts that are covering the firm, Marketbeat.com reports. Nine analysts have rated the stock with a buy rating. The average 12-month target price among brokers that have updated tOctober 29, 2024 | marketbeat.com Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address EYPT Media Mentions By Week EYPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EYPT News Sentiment▼0.460.68▲Average Medical News Sentiment EYPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EYPT Articles This Week▼54▲EYPT Articles Average Week Get EyePoint Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TXG News TRNS News CTKB News LAB News AEHR News SENS News ALNT News QTRX News QSI News NAUT News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EYPT) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding EyePoint Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share EyePoint Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EYPT Stock Alerts